Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)

被引：0
|
作者：
Xiang Zhang
Lotte C. A. Stiekema
Erik S. G. Stroes
Albert K. Groen
机构：
[1] Amsterdam University Medical Center,Department of Experimental Vascular Medicine
[2] University of Amsterdam,Human and Animal Physiology
[3] Wageningen University,Department of Vascular Medicine
[4] Amsterdam University Medical Center,undefined
[5] University of Amsterdam,undefined
来源：
Lipids in Health and Disease | / 19卷
关键词：
PCSK9 antibodies; Evolocumab; Lipoprotein(a); Metabolomics; VLDL;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] PCSK9 inhibition in PAD
    Karina Huynh
    Nature Reviews Cardiology, 2018, 15 : 4 - 5
  • [22] The promises of PCSK9 inhibition
    Petrides, Francine
    Shearston, Kate
    Chatelais, Mathias
    Guilbaud, Florian
    Meilhac, Olivier
    Lambert, Gilles
    CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (04) : 307 - 312
  • [23] Update on PCSK9 inhibition
    Katzmann, Julius L.
    Custodis, Florian
    Schirmer, Stephan H.
    Laufs, Ulrich
    HERZ, 2022, 47 (03) : 196 - 203
  • [24] Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome
    Ziogos, E.
    Chelko, S. P.
    Walsh, E.
    Engel, M.
    Gerstenblith, G.
    Halushka, M. K.
    Leucker, T. M.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1281 - 1281
  • [25] The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
    Momtazi-Borojeni, Amir Abbas
    Banach, Maciej
    Ruscica, Massimiliano
    Sahebkar, Amirhossein
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (10) : 1199 - 1208
  • [26] Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
    Waldmann, Elisa
    Wu, Liya
    Busygina, Kristina G.
    Altenhofer, Julia
    Henze, Kerstin
    Folwaczny, Alexander
    Parhofer, Klaus
    PLOS ONE, 2022, 17 (03):
  • [27] Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial -
    Keech, Anthony C.
    Oyama, Kazuma
    Sever, Peter S.
    Tang, Minao
    Murphy, Sabina A.
    Hirayama, Atsushi
    Lu, Chen
    Tay, Leslie
    Deedwania, Prakash C.
    Siu, Chung-Wah
    Pineda, Armando Lira
    Choi, Donghoon
    Charng, Min-Ji
    Amerena, John
    Ahmad, Wan Azman Wan
    Chopra, Vijay K.
    Pedersen, Terje R.
    Giugliano, Robert P.
    Sabatine, Marc S.
    CIRCULATION JOURNAL, 2021, 85 (11) : 2063 - +
  • [28] Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction
    Nakamura, Akihiro
    Kanazawa, Masanori
    Kagaya, Yuta
    Kondo, Masateru
    Sato, Kenjiro
    Endo, Hideaki
    Nozaki, Eiji
    JOURNAL OF CARDIOLOGY, 2020, 76 (04) : 395 - 401
  • [29] EVOLOCUMAB PHARMACOKINETICS AND ITS EFFECTS ON LDL-C AND PCSK9 LOWERING IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT.
    Emery, M. G.
    Gibbs, J. P.
    Slatter, J. G.
    Hamilton, L.
    Wasserman, S. M.
    Geller, M.
    Dias, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S69 - S69
  • [30] A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice
    Essalmani, Rachid
    Weider, Elodie
    Marcinkiewicz, Jadwiga
    Chamberland, Ann
    Susan-Resiga, Delia
    Roubtsova, Anna
    Seidah, Nabil G.
    Prat, Annik
    BIOLOGICAL CHEMISTRY, 2018, 399 (12) : 1363 - 1374
12345